# Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT03776812** · PHASE2 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 178 (actual)

## Conditions studied

- Recurrent Ovarian Cancer
- Recurrent Fallopian Tube Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Relacorilant
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT03776812
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2021-03-16
- **Final completion:** 2023-07-12
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776812, "Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03776812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*